A Change of Osteocalcin (OC) and Tartrate Resistant Acid Phosphatase 5b (TRACP-5b) with the Menstrual Cycle

Abstract

Bone metabolism markers associated with 4 menstrual cycle phases were evaluated in 14 healthy young females without menstrual disorder. Menstrual cycle phases were confirmed with basal body temperature for 3 months, luteinizing hormone kits, and sexual hormone concentrations of serum. The bone metabolism markers used were osteocalcin (OC), which was measured by immunoradiometric assay (IRMA), and tartrate resistant acid phosphatase 5b (TRACP-5b), which was measured by enzyme immunometric assay (EIA). The highest values of OC and TRACP-5b were observed in the ovulation phase, and TRACP-5b increased significantly when compared with levels in the menstrual phase (p<0.05). Furthermore, the changes in sex-hormone secretion involved in OC and TRACP-5b showed specific patterns during the menstrual cycle. In other words, TRACP-5b levels are influenced by sex hormones produced during the menstrual period and are based on the bone-formation status. Therefore, it is presumed that the TRACP-5b levels during ovulation play a central role in bone formation and bone metabolism.

Key words

menstrual cycle - sex hormone - ovulatory phase - osteocalcin - TRACP-5b

• References

• 1 Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536
• 2 Veldhuis JD, Hudson SB, Erickson D, Bailey JN, Reynolds GA, Bowers CY. Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women. Am J Physiol Endocrinol Metab 2009; 297: E367-E374
• 3 Monninkhof EM, Velthuis MJ, Peeters PH, Twisk JW, Schuit AJ. Effect of exercise on postmenopausal sex hormone levels and role of body fat: a randomized controlled trial. J Clin Oncol 2009; 27: 4492-4499
• 4 Farage MA, Neill S, MacLean AB. Physiological changes associated with the menstrual cycle: a review. Obstet Gynecol Surv 2009; 64: 58-72
• 5 Notelovitz M, John VA, Good WR. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. Menopause 2002; 9: 343-353
• 6 Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. Osteoporos Int 2001; 12: 251-258
• 7 Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002; 53: 550-557
• 8 Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, D’Anna R, Lasco A, Squadrito G, Gaudio A, Cancellieri F, Arcoraci V, Squadrito F. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-1519
• 9 Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women’s Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002; 288: 321-333
• 10 Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-12
• 11 Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M. Guidelines for the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 2005; 23: 97-104
• 12 Nishizawa Y, Inaba M, Ishii M, Yamashita H, Miki T, Goto H, Yamada S, Chaki O, Kurasawa K, Mochizuki Y. Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J Bone Miner Metab 2008; 26: 265-270
• 13 Schlemmer A, Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C. Possible variation in bone resorption during the normal menstrual cycle. Acta Endocrinol 1993; 129: 388-392
• 14 Massafra C, De Felice C, Agnusdei DP, Gioia D, Bagnoli F. Androgens and osteocalcin during the menstrual cycle. J Clin Endocrinol Metab 1999; 84: 971-974
• 15 Gorai I, Taguchi Y, Chaki O, Kikuchi R, Nakayama M, Yang BC, Yokota S, Minaguchi H. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab 1998; 83: 326-332
• 16 Gorai I, Chaki O, Nakayama M, Minaguchi H. Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 1995; 57: 100-104
• 17 Ibuka E, Ohida T, Miyake T, Suzuki K, Motojima S, Harano S, Yokoyama E, Kaneita Y, Kaneko A, Takeda F. Relationships between finding of calcaneal quantitative ultrasound and lifestyle in Japanese college students. Nihon Koshu Eisei Zasshi 2004; 51: 764-773
• 18 Bolton JG, Patel S, Lacey JH, White S. A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa. Osteoporos Int 2005; 16: 1955-1962
• 19 Cobb KL, Bachrach LK, Greendale G, Marcus R, Neer RM, Nieves J, Sowers MF, Brown Jr BW, Gopalakrishnan G, Luetters C, Tanner HK, Ward B, Kelsey JL. Disordered eating, menstrual irregularity, and bone mineral density in female runners. Med Sci Sports Exerc 2003; 35: 711-719
• 20 Villareal DT, Fontana L, Weiss EP, Racette SB, Steger-May K, Schechtman KB, Klein S, Holloszy JO. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med 2006; 166: 2502-2510
• 21 Igarashi H. Sterility/Internal secretion. Nihon Sanka Fujinka Gakkai Zasshi 2010; 62: 63-76
• 22 Jaffe CA, Ocampo-Lim B, Guo W, Krueger K, Sugahara I, Demott-Friberg R, Barkan AL. Growth hormone secretory dynamics over the menstrual cycle. Endocr J 2000; 47: 549-556
• 23 Bao AM, Liu RY, van Someren EJ, Hofman MA, Cao YX, Zhou JN. Diurnal rhythm of free estradiol during the menstrual cycle. Eur J Endocrinol 2003; 148: 227-232
• 24 Ishihara H. Non-collagenous protein and bone quality. The Bone 2010; 24: 247-251
• 25 Mochizuki Y, Nishizawa Y, Oishi A, Ohtsu R, Miura T, Igarashi Y, Inaba N. Day-to-day and diurnal variations of serum tartrate-resistant acid phosphatase type 5b with newly developed TRACP-5b kit and their comparison to other bone metabolic markers. Jap J Med Pharmaceut Sci 2005; 54: 895-902
• 26 Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005; 16: 372-379
• 27 Evans MJ, Harris HA, Miller CP, Karathanasis SK, Adelman SJ. Estrogen receptors alpha and beta have similar activities in multiple endothelial cell pathways. Endocrinology 2002; 143: 3785-3795
• 28 Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001; 98: 13960-13965
• 29 Chiang K, Parthasarathy S, Santanam N. Estrogen, neutrophils and oxidation. Life Sci 2004; 75: 2425-2438
• 30 Sontakke AN, Tare RS. A duality in the roles of reactive oxygen species with respect to bone metabolism. Clin Chim Acta 2002; 318: 145-148
• 31 Koshihara Y, Hoshi K, Okawara R, Ishibashi H, Yamamoto S. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol 2003; 176: 339-348
• 32 Karowicz-Bilinska A, Plodzidym M, Krol J, Lewinska A, Bartosz G. Changes of markers of oxidative stress during menstrual cycle. Redox Rep 2008; 13: 237-240
• 33 Tölle M, Pawlak A, Schuchardt M, Kawamura A, Tietge UJ, Lorkowski S, Keul P, Assmann G, Chun J, Levkau B, van der Giet M, Nofer JR. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 2008; 28: 1542-1548
• 34 Dolezal BA, Potteiger JA. Concurrent resistance and endurance training influence basal metabolic rate in nondieting individuals. J Appl Physiol 1998; 85: 695-700
• 35 Klein KO, Larmore KA, de Lancey E, Brown JM, Considine RV, Hassink SG. Effect of obesity on estradiol level, and its relationship to leptin, bone maturation, and bone mineral density in children. J Clin Endocrinol Metab 1998; 83: 3469-3475
• 36 Wallace BA, Cumming RG. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000; 67: 10-18
• 37 Whipple TJ, Le BH, Demers LM, Chinchilli VM, Petit MA, Sharkey N, Williams NI. Acute effects of moderate intensity resistance exercise on bone cell activity. Int J Sports Med 2004; 25: 496-501
• 38 Suzuki K, Kumanogoh A, Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat Immunol 2008; 9: 17-23
• 39 Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, Takayanagi H. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nature Medicine 2011; 17: 1473-1480
• 40 Hayden JM, Mohan S, Baylink DJ. The insulin-like growth factor system and the coupling of formation to resorption. Bone 1995; 17: 93S-98S
• 41 Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008; 473: 201-209